Exploration of the Optimal Minimum Lymph Node Count after Colon Cancer Resection for Patients Aged 80 Years and Older

Xu Guan1,2, Wei Chen3, Zheng Jiang2, Zheng Liu2, Dazhuang Miao4, Hanqing Hu1, Zhixun Zhao1, Runkun Yang1 & Xishan Wang1,2

The elderly colon cancer (CC) patients are increasing and represent a heterogeneous patient group. The objectives of this study were to identify the features of lymph node examination and to explore the optimal minimum lymph node count after CC resection for patients aged ≥80. Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 65719 CC patients in stage I-III between 2004 and 2012, 26.0% of patients were aged ≥80. The median node count decreased with increasing age, which were 25.5, 20.2, 17.8 and 16.9 for patients aged 20–39, 40–59, 60–79, and ≥80. The rate of ≥12 nodes and the rate of node positivity for patients aged ≥80 were obviously lower than younger patients. Using X-tile analysis, we determined 9 nodes as the optimal node count for patients aged ≥80. Then, we compared the 5-year cancer specific survival (CSS) between patients with ≥9 nodes and <9 nodes. The results showed the 5-year CSSs were improved for patients with ≥9 nodes. Furthermore, the rate of node positivity and survival under the 9-node measure were equal to 12-node measure. Therefore, the lymph node examination should be discriminately evaluated for elder patients, and 9-node measure was available for patients aged ≥80.

Elderly patients currently account for a significant proportion of patients who are diagnosed with colon cancer (CC), which bring a challenge of dealing with an aging population to medical oncologists. The US Preventive Services Task Force guidelines have showed that the percentage of colorectal cancer patients aged ≥75 increased from 29% to 40% between 1973 and 2007. With the increasing and large proportion of the elderly CC patients, more attention should be paid for this group of patients. However, many questions regarding to the elder patients, especially for patients aged ≥80, were still not well defined.

Accurate cancer staging is highly dependent on sufficient number of lymph nodes examination to detect the positive nodes. Positive nodes are closely associated with adverse prognosis and more appropriate use of adjuvant chemotherapy for CC patients. Therefore, numerous studies have attempted to explore the optimal minimum lymph node count that contribute to improved tumor staging and survival outcomes, but individual studies varied widely in their recommendations for lymph node count to accurately detect the positive nodes. The National Comprehensive Cancer Network (NCCN) guideline and the American Society of Clinical Oncology (ASCO) advocate that 12 regional lymph nodes should be the necessary minimum node count for quality evaluation of CC resection. However, lymph node examination of CC was influenced by several factors, including patient-, tumor-, and treatment-related factors. Among them, age has been considered as one important influential factor on node examination. The disparity in nodal examination gradually begs the question of whether the 12-node measure is an appropriate threshold for all CC patients.

Elder CC patients have distinct characteristics that need to be taken into account regarding lymph node evaluation, especially for patients aged ≥80. However, little attention has been paid to this issue, which contributed to a distinct lack of data on these elder patients. Accordingly, with data from the Surveillance, Epidemiology, and End Results (SEER) database, we identified 65719 CC patients in stage I-III between 2004 and 2012, 26.0% of patients were aged ≥80. The median node count decreased with increasing age, which were 25.5, 20.2, 17.8 and 16.9 for patients aged 20–39, 40–59, 60–79, and ≥80. The rate of ≥12 nodes and the rate of node positivity for patients aged ≥80 were obviously lower than younger patients. Using X-tile analysis, we determined 9 nodes as the optimal node count for patients aged ≥80. Then, we compared the 5-year cancer specific survival (CSS) between patients with ≥9 nodes and <9 nodes. The results showed the 5-year CSSs were improved for patients with ≥9 nodes. Furthermore, the rate of node positivity and survival under the 9-node measure were equal to 12-node measure. Therefore, the lymph node examination should be discriminately evaluated for elder patients, and 9-node measure was available for patients aged ≥80.
Results

Patient characteristics. We totally identified 65719 patients diagnosed with stage I–III CC from 2004 to 2012 in the SEER database, 17058 patients (26.0%) were aged ≥80 years. Baseline characteristics significantly differed among four subgroups (Table 1). Patients aged ≥80 were more common seen in female patients (64.1%), this proportion was obviously higher than other three subgroups. The proportion of stage III patients gradually decreased with age, varying from 51.1% in aged 20–39 subgroup to 32.6% in aged ≥80 subgroup. Overall, the largest proportions were white (80.4%), adenocarcinoma (86.5%), grade II (67.0%) right side (82.0%) and T3/T4 (71.2%), distributions of these characteristics were fairly uniform across four subgroups.

The comparisons of lymph node evaluation among different age subgroups. In this study, patients with adequate lymph node count (≥12) accounted for 77.9% in all patients, and hence it was confidently staged according to their nodal status. The median number of lymph node count was decreased with increasing age, which were 25.5, 20.2, 17.8 and 16.9 for patients aged 20–39, 40–59, 60–79, and ≥80, respectively (P < 0.001) (Fig. 1A). For lymph node positivity, the proportion of patients with at least one node positive were 51.1%, 41.6%, 34.6%, and 32.6% for patients aged 20–39, 40–59, 60–79, and ≥80 (P < 0.001) (Fig. 1B). The rate of ≥12 nodes was the lowest for patients aged ≥80 compared with the younger patients (P < 0.001) (Fig. 1C). These results showed that patients aged ≥80 were associated with poor lymph node harvest and lower rate of node positivity. Therefore, the elderly patient certainly faced greater challenge of harvesting adequate lymph nodes (≥12 nodes) compared with younger patients. In other words, the standard 12-node measure may be not reasonable to be

Table 1. Characteristics of CC patients in the SEER database: 2004–2012. Others: American Indian/AK Native, Asian/Pacific Islander.

| Characteristics          | 20–39 years N = 1271 (%) | 40–59 years N = 13743 (%) | 60–79 years N = 33647 (%) | ≥80 years N = 17058 (%) | Total N = 65719 (%) |
|--------------------------|---------------------------|----------------------------|---------------------------|-------------------------|---------------------|
| Gender                   |                           |                            |                           |                         |                     |
| Male                     | 666 (52.4)                | 7444 (54.2)                | 16498 (49.0)              | 6119 (35.9)             | 30727 (46.8)        |
| Female                   | 605 (47.6)                | 6299 (45.8)                | 17149 (51.0)              | 10939 (64.1)            | 34992 (53.2)        |
| Race                     |                           |                            |                           |                         |                     |
| White                    | 922 (72.5)                | 9907 (72.1)                | 26996 (80.2)              | 14987 (87.9)            | 52812 (80.4)        |
| Black                    | 193 (15.2)                | 2652 (19.3)                | 4198 (12.5)               | 1111 (6.5)              | 8154 (12.4)         |
| Others                   | 142 (11.2)                | 1100 (8.0)                 | 2341 (7.0)                | 930 (5.4)               | 4513 (6.9)          |
| Unknown                  | 14 (1.1)                  | 84 (0.6)                   | 112 (0.3)                 | 30 (0.2)                | 240 (0.3)           |
| AJCC Stage               |                           |                            |                           |                         |                     |
| Stage I                  | 148 (11.7)                | 3153 (22.9)                | 9038 (26.9)               | 3961 (23.2)             | 16300 (24.8)        |
| Stage II                 | 473 (37.2)                | 4879 (35.5)                | 12971 (38.5)              | 7535 (44.2)             | 25858 (39.3)        |
| Stage III                | 650 (51.1)                | 5711 (41.6)                | 11638 (34.6)              | 5562 (32.6)             | 23561 (35.9)        |
| Grade                    |                           |                            |                           |                         |                     |
| Grade I                  | 70 (5.5)                  | 1281 (9.3)                 | 3114 (9.3)                | 1373 (8.0)              | 5838 (8.9)          |
| Grade II                 | 803 (63.2)                | 9449 (68.8)                | 22819 (67.8)              | 10997 (64.5)            | 44068 (67.0)        |
| Grade III                | 315 (24.8)                | 2280 (16.6)                | 5968 (17.7)               | 3846 (22.6)             | 12409 (18.9)        |
| Grade IV                 | 45 (3.5)                  | 267 (1.9)                  | 697 (2.1)                 | 445 (2.6)               | 1454 (2.2)          |
| Unknown                  | 38 (3.0)                  | 466 (3.4)                  | 1049 (3.1)                | 397 (2.3)               | 1950 (3.0)          |
| Histology type           |                           |                            |                           |                         |                     |
| Adenocarcinoma           | 1027 (80.8)               | 12011 (87.4)               | 29304 (87.1)              | 14521 (85.1)            | 56863 (86.5)        |
| Mucous/signet-ring cell  | 230 (18.1)                | 1660 (12.1)                | 4112 (12.2)               | 2368 (13.9)             | 8370 (12.8)         |
| Other types              | 14 (1.1)                  | 72 (0.5)                   | 231 (0.7)                 | 169 (1.0)               | 486 (0.7)           |
| Tumor location           |                           |                            |                           |                         |                     |
| Left-sided colon         | 404 (31.8)                | 3597 (26.2)                | 5848 (17.4)               | 1973 (11.6)             | 11822 (18.0)        |
| Right-sided colon        | 867 (68.2)                | 10146 (75.8)               | 27799 (82.6)              | 15085 (88.4)            | 53897 (82.0)        |
| T stage                  |                           |                            |                           |                         |                     |
| T1/T2                    | 199 (15.7)                | 3813 (27.7)                | 10459 (31.1)              | 4484 (26.3)             | 18955 (28.8)        |
| T3/T4                    | 1072 (84.3)               | 9930 (72.3)                | 23188 (68.9)              | 12574 (73.7)            | 46764 (71.2)        |
| N stage                  |                           |                            |                           |                         |                     |
| N0                       | 621 (48.9)                | 8032 (58.4)                | 22009 (65.4)              | 11496 (67.4)            | 42158 (64.1)        |
| N1/N2                    | 650 (51.1)                | 5711 (41.6)                | 11638 (34.6)              | 5562 (32.6)             | 23561 (35.9)        |
equally required for the elderly patients as young patients. Accordingly, we tentatively explored an optimal cut-off node count for patients aged \( \geq 80 \), instead of 12 nodes.

Identification of the optimal cut-off point of lymph node count for patients aged \( \geq 80 \).

We applied X-tile analysis to determine the optimal cut-off node count for prediction of CSS according to different lymph node count. The result showed that 9 was the optimal cut-off node count for patients aged \( \geq 80 \) (\( P < 0.001 \)) (Fig. 2). Therefore, this cut-off value was used as prognostic factor for further analysis in patients aged \( \geq 80 \).

Prognostic impact of the 9-node measure on CCS for patients aged \( \geq 80 \).

The median CSSs were 55.0 months for patients with \( \geq 9 \) nodes, and 39.0 months for patients with \(< 9 \) nodes. The 5-year CSS was 46.7\% for patients with \( \geq 9 \) nodes and 38.6\% for those with \(< 9 \) nodes (\( P < 0.001 \)) (Fig. 3A). Then, we separately evaluated the effect of 9-node measure on CSS of patients in different tumor staging. The results indicated that patients in stage I, II and III all obtained survival benefit from \( \geq 9 \) nodes compared with patients who examined \(< 9 \) nodes (Fig. 3B–D).

Identification of risk factors for survival for patients aged \( \geq 80 \).

Using univariate and multivariate regression analyses, we identified the risk factors that associated with long-term survival outcomes for patients aged \( \geq 80 \). The results showed that retrieval of \(< 9 \) nodes was identified as independent adverse prognostic factors in patients aged \( \geq 80 \) (Table 2). In addition, characteristics including black, male, stage II/III, T3/4 stage, N1/2 and grade II/III/IV were all identified independent risk factors for survival in patients aged \( \geq 80 \).

Comparisons of the rate of node positivity and survival between 9-node measure and 12-node measure.

Adequate lymph node retrieval was higher related to accurate tumor staging and improved
long-term survival. To confirm the value of 9-node measure for patient aged ≥80, we separately evaluate the effect of lymph node count on the rate of node positivity and long-term survival. Firstly, we separately calculated the rate of node positivity based on different node count from ≥6 to ≥15. The result showed that the rate of node positivity changed between 33.0% and 33.5% according to the node count from ≥6 to ≥15 (Fig. 4). The rate of node positivity was 33.3% for patient with ≥9 nodes, which was higher than patients with ≥12 nodes (33.2%). The detailed information was shown in Supplementary Table 1. This result indicated that the 9-node measure did not reduce the rate of node positivity compared with the standard 12-node measure for patients aged ≥80. Due to patients with positive lymph node are belong to stage III, the rate of node positivity is equal to the proportion of stage III patients in all patients. For the elderly patients, the proportion of stage III patients was not reduced by using the 9-node measure. Examining ≥9 nodes is therefore enough to determine tumor stage and could be considered as adequate surgery.

In addition, we assessed the effect of node count on the long-term survival outcomes. The 3-, 5- and 8-year CCSs were separately calculated according to node count from ≥6 to ≥15. For patients with ≥9 nodes, the 3-, 5- and 8-year CCSs were 61.6%, 46.7% and 29.4%. For patients with ≥12 nodes, the 3-, 5- and 8-year CCSs were 62.6%, 47.8% and 29.9% (Fig. 5). Therefore, the results showed that the long-term survivals were similar between these two groups. This result suggested that although the increased node count was associated with better survival outcomes, the long-term survival of patients with ≥9 nodes was not obviously decreased compared with those who examined ≥12 nodes for patients aged ≥80.

**Survival comparison in patients with different nodes examined.** Furthermore, we performed the survival comparison in patients with different nodes examined (<9 nodes vs. 9–12 nodes vs. ≥12 nodes). The Supplementary Figure 1 showed that the 5-year CSS of patients with ≥12 nodes examined was 47.8%, which was significantly higher than patients with 9–12 nodes (40.5%) and patients with <9 nodes (38.6%). This result suggested that the number of nodes examined was positively associated with survival outcomes for the elderly patients.

**Discussion**
CC patients aged ≥80 represented a large proportion in all patients. Here, we totally identified 17058 CC patients aged ≥80, which accounted for 26.0% in all patients from 2004 to 2012. Elder patients, especially for patients aged ≥80, not only has been thought as an independent prognostic factor regarding with survival, but also has
been associated with different clinical and histological features\(^9,13-15\). Therefore, patients aged \(\geq 80\) were highly heterogeneous population, which should be discriminately evaluated in the consideration of cancer diagnosis and treatment.

Lymph node examination after CC resection is considered to be one crucial factor in assessing the accuracy of tumor staging, which determine further therapeutic planning and prognosis. Patients with positive nodes have to accept adjuvant chemotherapy regarding with the higher risk of tumor recurrence and metastasis\(^16\). Current guidelines advocate that the lymph node examination should meet the requirement of at least 12 nodes examined in CC specimen. However, the lymph node evaluation was highly heterogeneous, which was affected by several factors. Age was thought to be an important factor that influenced the lymph node examination of CC. The CC patients who aged \(\geq 80\), had obviously lower lymph node harvest compared with the younger patients\(^11\). In this study, the results showed that the median number of lymph nodes examined was 16.9 for patients aged \(\geq 80\), which was significantly fewer than other three younger patient groups. A possible explanation for this result may be related to a weaker immunological response to a malignant tumor in the elderly\(^17\). In addition, older age might also contribute to more limited resections compared with younger patients\(^18,19\). Whatever the potential reasons for poor node harvest in the elderly, it was the fact that a retrieval of \(\geq 12\) nodes was certainly difficult for this group of patients. Therefore, it might be unreasonable to request that the 12-node measure was equally used for both patients aged \(\geq 80\) and the younger patients.

| Characteristic | Univariate analysis | Multivariate analysis |
|---------------|---------------------|----------------------|
|               | HR [95% CI] | P            | HR [95% CI] | P            |
| Node examined | <9               | 1               | <0.001     | 1               | <0.001     |
|               | \(\geq 9\)      | 0.797 [0.764–0.832] | <0.001     | 0.766 [0.733–0.800] | <0.001     |
| Gender        | Female           | 1               | <0.001     | 1               | <0.001     |
|               | Male             | 1.150 [1.101–1.202] | 1.173 [1.122–1.226] | 1.173 [1.122–1.226] | <0.001     |
| Race          | White            | 1               | 1          | 1               | <0.001     |
|               | Black            | 1.140 [1.048–1.240] | 1.145 [1.052–1.246] | 1.145 [1.052–1.246] | <0.001     |
|               | Others           | 0.749 [0.675–0.832] | 0.726 [0.654–0.806] | 0.726 [0.654–0.806] | <0.001     |
| AJCC stage    | Stage I          | 1               | 1          | 1               | <0.001     |
|               | Stage II         | 1.250 [1.178–1.327] | 1.124 [1.016–1.249] | 1.124 [1.016–1.249] | <0.001     |
|               | Stage III        | 1.983 [1.868–2.106] | 1.353 [1.185–1.545] | 1.353 [1.185–1.545] | <0.001     |
| T stage       | T1/T2            | 1               | 1          | 1               | <0.001     |
|               | T3/T4            | 1.480 [1.405–1.558] | 1.332 [1.348–1.742] | 1.332 [1.348–1.742] | <0.001     |
| N stage       | N0               | 1               | <0.001     | 1               | <0.001     |
|               | N1/N2            | 1.710 [1.636–1.787] | 1.743 [1.678–1.797] | 1.743 [1.678–1.797] | <0.001     |
| Tumor location| Right-sided colon| 1               | 0.123      | 1               | <0.001     |
|               | Left-sided colon | 1.053 [0.986–1.124] | 1.053 [0.986–1.124] | 1.053 [0.986–1.124] | 0.123      |
| Histological type | Adenocarcinoma | 1 | 0.143 | 1 | <0.001 |
|               | Mucous/signet-ring cell | 1.059 [0.997–1.125] | 1.059 [0.997–1.125] | 1.059 [0.997–1.125] | 0.143      |
| Grade         | Grade I          | 1               | 1          | 1               | <0.001     |
|               | Grade II         | 1.067 [0.983–1.158] | 1.003 [0.924–1.090] | 1.003 [0.924–1.090] | 0.001      |
|               | Grade III        | 1.336 [1.223–1.460] | 1.159 [1.059–1.269] | 1.159 [1.059–1.269] | <0.001     |
|               | Grade IV         | 1.662 [1.432–1.930] | 1.442 [1.238–1.680] | 1.442 [1.238–1.680] | <0.001     |

Table 2. Univariate and multivariate analyses for CC patients aged \(\geq 80\). Others: American Indian/AK Native, Asian/Pacific Islander.

Figure 4. The trend of node positivity rate according to lymph node count from \(\geq 6\) to \(\geq 15\).
In this study, we tentatively explore the optimal cut-off node count, instead of 12 nodes, for patients aged ≥80 based on the prediction of CSS. Our results identified that 9 nodes was the optimal cut-off point for patients aged ≥80. All CC patients in stage I, II and III all could obtain much survival benefit from examining ≥9 nodes, and examining <9 nodes was also identified as independent adverse prognostic factors in patients aged ≥80. In addition, 9-node measure did not decrease the chance of obtaining positive lymph node compared with the 12-node measure. Hence, the use of the 9-node measure might be more reasonable for patients aged ≥80.

In identifying the difference of lymph node examination for CC patients aged ≥80, the SEER databases provide sufficient CC cases with uniformly collected data, which highly represented the CC patients across the United States. However, there had some potential limitations in SEER database including lack of information regarding the adjuvant chemotherapy for CC patients, lack of central histological review, and lack of information on operative morbidity and comorbidities. The study may also be confounded by other contributing factors, such as general ASA status, which may indirectly affect the lymph node examination in the elderly patients. These noted limitations in SEER are common to most of other large epidemiological databases, which have been well addressed in literatures. Furthermore, the selection biases could not be avoided in this retrospective cohort study, because the elderly patients who underwent CC resection should be fitter, and the radical surgery of CC might be not regularly performed for this group of patients as young patients. Despite these limitations, SEER remains a valuable resource to analyze trends and patterns in patient characteristics, tumor features, cancer treatments, and survival outcomes.

In conclusion, this population-based study demonstrated that patients aged ≥80 accounted for a large proportion of CC patients, they had obviously lower rate of ≥12 nodes examined compared with the younger patients. Instead of 12-node measure, we identified that the 9-node measure may be more feasible and reasonable in patients aged ≥80. However, whether this finding could impact the adjuvant treatment decision-making for the elderly patient who cannot tolerate chemotherapy, more investigations of outcomes for this group of CC patients are still need to be performed.

Materials and Methods

Data sources. We extracted cancer data from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2012. The SEER database includes the information regarding cancer incidence, treatment and survival outcomes from 17 population-based cancer registries, which represented 28% of the US population. Data collected from the SEER database do not require informed patient consent, because they were anonymized and de-identified prior to release.

This study was approved by the Ethics Committee of The Second Affiliated Hospital of Harbin Medical University institutional review board. The SEER database is openly accessed, and we have got permission to access the cancer data from the SEER database by National Cancer Institute, and the reference number was 11228-Nov2014. All methods were performed in accordance with the relevant guidelines and regulations of SEER database.

Study population. We collected cases based on the International Classification of Diseases Oncology, Third Edition (ICD-O-3) codes for anatomic site (colon excluding rectum). We used the term “age” which was referred to “age at diagnosis” in SEER database. Patients were divided into four age subgroups by 20-year intervals, including 20–39, 40–59, 60–79, ≥80. Patients included in this study should undergo radical resection of the CC as the first course of therapy, which were more available and accurate for the lymph node evaluation. Race/ethnicity was categorized as white, black and Asian/Pacific Islander (API), including American Indian/Alaska Natives. Right CC included tumors being located at cecum, ascending colon, hepatic flexure and transverse colon. Left CC included tumors being located at splenic flexure, descending colon and sigmoid colon. The exclusion criteria should include patients: dead due to other causes, with an unknown number of nodes examined, aged <20 years, who received preoperative radiotherapy in the consideration of the decreased number of node examined, and who underwent a local procedure, partial colon resection or total colectomies.
Statistical analysis. The comparisons of lymph node evaluation among different age subgroups were performed in three ways including the median number of lymph node, the rate of ≥12 lymph nodes and the rate of node positivity. All categorical variables were compared between groups using χ² test. The cancer specific survival (CSS) was defined as the time from the CC diagnosis until cancer recurrence or metastasis, cancer-associated death and the end of follow up. The 5-year CSS was estimated with Kaplan-Meier method and log-rank test was used to compare the difference of CSS curves. Univariate and multivariate Cox’s regression model were performed to estimate hazard rate (HR) and exact 95% confidence intervals (CIs). P < 0.05 (two sides) was considered to be statistical significance. The statistical analyses were conducted with SPSS statistical software, version 20 (IBM Corp, Armonk, NY, USA).

X-tile plots is a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization, which illustrates the presence of substantial patients subpopulations and shows the robustness of the relationship between a marker and survival outcome by construction of a two dimensional projection of every possible subpopulation. X-tile plots divided population into different divisions based on every possible cutoff point. X-tile data are presented in a right triangular grid where each point represents a different cutoff point. The X-tile plots statistically test each divisions based on each cutoff point. All possible divisions of the cutoff point are tested. Then, a χ² value is calculated for every possible division of the population. The optimal cutoff node count for survival was calculated by selecting minimum P value with the maximum χ² value.

References
1. Kumar, R. et al. A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. *Cancer* **119**, 722–728 (2013).
2. Shellnut, J. K., Wasvary, H. J., Grodsky, M. B., Boura, J. A. & Priest, S. G. Evaluating the age distribution of patients with colorectal cancer: are the United States Preventative Services Task Force guidelines for colorectal cancer screening appropriate? *Dis Colon Rectum* **53**, 5–8 (2010).
3. Lykke, J., Roukjaer, O. & Jess, P. The relation between lymph node status and survival in Stage I–III colon cancer: results from a prospective nationwide cohort study. *Dis Colon Rectum* **15**, 59–66 (2013).
4. Le Voyer, T. E. et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol* **21**(15), 2912–2919 (2003).
5. Bilmoria, K. Y. et al. Lymph node evaluation as a colon cancer quality measure: a national hospital report card. *J Natl Cancer Inst* **100**, 1310–1317 (2008).
6. Ashktorab, H. et al. Lymph nodes’ evaluation in relation to colorectal cancer staging among African Americans. *BMC Cancer* **15**, 976 (2015).
7. Swanson, R. S., Compton, C. C., Stewart, A. K. & Bland, K. I. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. *Ann Surg Oncol* **10**, 65–71 (2003).
8. Joseph, N. E. et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. *Ann Surg Oncol* **10**, 213–218 (2003).
9. Caplin, S., Cerottini, J. P., Bosman, F. T., Constanda, M. T. & Givel, J. C. For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. *Cancer* **83**, 666–672 (1998).
10. Nedrebo, B. S. et al. Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. *Colorectal Dis* **15**, e301–308 (2013).
11. Tekkis, P. P. et al. A national study on lymph node retrieval in resectional surgery for colorectal cancer. *Dis Colon Rectum* **49**, 1673–1681 (2006).
12. Khan, H., Olczewski, A. J. & Somasundar, P. Lymph node involvement in colon cancer patients decreases with age; a population based analysis. *Eur J Surg Oncol* **40**, 1474–1480 (2014).
13. Ikeda, H. et al. Curative colorectal resections in patients aged 80 years and older: clinical characteristics, morbidity, mortality and risk factors. *Int J Colorectal Dis* **28**, 941–947 (2013).
14. Kotsake, K., Amano, M., Ozawa, H., Kobayashi, H. & Sugihara, K. Tumor characteristics, treatment patterns and survival of patients aged 80 years or older with colorectal cancer. *Colorectal Dis* **17**, 205–215 (2015).
15. Arai, T. & Takubo, K. Clinicopathological and molecular characteristics of gastric and colorectal carcinomas in the elderly. *Pathol Int* **57**, 303–314 (2007).
16. Li Destri, G., De Carlo, I., Scillette, R., Scillette, B. & Puleo, S. Colorectal cancer and lymph nodes: the obsession with the number 12. *World J Gastroenterol* **20**, 653–660 (2014).
17. Morris, E. J., Maughan, N. J., Forman, D. & Quirke, P. Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist. *J Clin Oncol* **25**, 2573–2579 (2007).
18. Baxter, N. N. et al. Lymph node evaluation in colorectal cancer patients: a population-based study. *J Natl Cancer Inst* **97**, 219–225 (2005).
19. Chou, J. F. et al. Clinical and pathologic factors that predict lymph node yield after colorectal cancer resection. *J Natl Cancer Inst* **97**, 666–672 (2005).
20. Hankey, B. F., Ries, L. A. & Edwards, B. K. The surveillance, epidemiology, and end results program: a national resource. *Cancer Epidemiol Biomarkers Prev* **8**, 1117–1121 (1999).

Acknowledgements
The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER database. The interpretation of these data is the sole responsibility of the authors.

Author Contributions
X.G., W.C. and X.W. designed the research; X.G., Z.J., Z.Z., D.M. and H.H. performed the research; X.G., W.C., Z.J., Z.L., D.M., H.H., Z.Z., R.Y. and X.W. analyzed data and wrote the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Guan, X. et al. Exploration of the Optimal Minimum Lymph Node Count after Colon Cancer Resection for Patients Aged 80 Years and Older. Sci. Rep. 6, 38901; doi: 10.1038/srep38901 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016